科济生物医药（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress 2024-11-06 21:50
CARsgen® U.S. Clinical Holds Lifted by FDA 2024-11-01 09:33
CARsgen® Announces 2024 Interim Results 2024-08-29 20:50
CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel) 2024-08-19 20:50
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 2024-06-15 20:50
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO 2024-06-04 20:50
CARsgen Submitted Responses to FDA Observations 2024-04-29 20:50
CARsgen Announced 2023 Annual Results 2024-03-27 20:50
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma 2024-03-01 21:50
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting 2024-01-19 21:50
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection 2024-01-15 21:50
CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting 2023-12-12 21:50
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia 2023-12-04 21:50
CARsgen Announces Formation of its Clinical Advisory Board 2023-11-20 21:50
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival 2023-10-12 20:50
Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology 2023-09-21 16:00
CARsgen Announced 2023 Interim Results 2023-08-22 19:30
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S. 2023-05-18 20:50
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer 2023-05-05 20:50
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer 2023-04-20 20:50
1 2